logo.jpg
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
October 28, 2022 08:45 ET | Genmab A/S
Media Release COPENHAGEN, Denmark; October 28, 2022 Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamabEuropean Medicines Agency...
logo.jpg
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
October 18, 2022 06:35 ET | Genmab A/S
Company Announcement Net sales of DARZALEX® in the third quarter of 2022 totaled USD 2,052 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
logo.jpg
Major Shareholder Announcement
October 05, 2022 15:56 ET | Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 5, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
September 27, 2022 12:43 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 27, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,406 shares as a consequence of the exercise of employee warrants. The...
logo.jpg
Grant of Restricted Stock Units and Warrants to Employees in Genmab
September 20, 2022 15:20 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 20, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 19,782 restricted stock units and 19,789 warrants to employees...
logo.jpg
Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 10:53 ET | Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; September 6, 2022 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
logo.jpg
Completion of share buy-back program
September 01, 2022 12:27 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 1, 2022 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on August 31, 2022. On June 17, 2022 Genmab...
logo.jpg
Transactions in connection with share buy-back program
August 29, 2022 05:04 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 29, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
logo.jpg
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
August 24, 2022 14:52 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 24, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
logo.jpg
Transactions in connection with share buy-back program
August 22, 2022 05:50 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 22, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...